MX2022014113A - Dosificacion y administracion del anticuerpo anti-ctla-4 activable. - Google Patents

Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Info

Publication number
MX2022014113A
MX2022014113A MX2022014113A MX2022014113A MX2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A
Authority
MX
Mexico
Prior art keywords
ctla
dosing
antibody
administration
activatable anti
Prior art date
Application number
MX2022014113A
Other languages
English (en)
Inventor
Leonard P James
Michelle Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022014113A publication Critical patent/MX2022014113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos de dosificación y administración de un anticuerpo anti-CTLA-4 activable, tal como un ipilimumab activable.
MX2022014113A 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable. MX2022014113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12
PCT/US2021/031670 WO2021231346A1 (en) 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
MX2022014113A true MX2022014113A (es) 2022-12-08

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014113A MX2022014113A (es) 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Country Status (13)

Country Link
US (1) US20230192856A1 (es)
EP (1) EP4149544A1 (es)
JP (1) JP2023526232A (es)
KR (1) KR20230009432A (es)
CN (1) CN115515633A (es)
AR (1) AR122043A1 (es)
AU (1) AU2021270513A1 (es)
BR (1) BR112022022713A2 (es)
CA (1) CA3178649A1 (es)
IL (1) IL298126A (es)
MX (1) MX2022014113A (es)
TW (1) TW202207982A (es)
WO (1) WO2021231346A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031032A1 (en) * 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
SI3551660T1 (sl) * 2016-12-07 2024-02-29 Agenus Inc. Protitelesa proti antictla-4 in načini njihove uporabe

Also Published As

Publication number Publication date
JP2023526232A (ja) 2023-06-21
AU2021270513A1 (en) 2023-01-19
BR112022022713A2 (pt) 2023-03-28
WO2021231346A1 (en) 2021-11-18
CA3178649A1 (en) 2021-11-18
TW202207982A (zh) 2022-03-01
CN115515633A (zh) 2022-12-23
EP4149544A1 (en) 2023-03-22
US20230192856A1 (en) 2023-06-22
AR122043A1 (es) 2022-08-03
IL298126A (en) 2023-01-01
KR20230009432A (ko) 2023-01-17

Similar Documents

Publication Publication Date Title
MX2024008677A (es) Conjugados de camptotecina.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2018016364A (es) Anticuerpos anti-pd-l1.
WO2018234793A3 (en) Antibodies
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
PH12020551716A1 (en) Anti-ror antibody constructs
WO2018222722A3 (en) COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2018081531A3 (en) Methods for human t-cell activation
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2021000790A (es) Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
ZA202310057B (en) Anti-c-met antibody drug conjugates
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates
MX2022014113A (es) Dosificacion y administracion del anticuerpo anti-ctla-4 activable.
MX2023002705A (es) Combinaciones de lurbinectedina e inhibidor en el punto de control inmunitario.
WO2022090801A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
MX2023000617A (es) Anticuerpos anti-notch2 y metodos de uso.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.